Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

viatris inc. - VTRS

VTRS

Close Chg Chg %
13.13 0.24 1.83%

Closed Market

13.37

+0.24 (1.83%)

Volume: 8.36M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: viatris inc. - VTRS

VTRS Key Data

Open

$13.14

 Day Range

13.13 - 13.50

52 Week Range

9.08 - 13.62

 Market Cap

$15.82B

Shares Outstanding

1.19B

 Public Float

1.16B

Beta

0.93

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.74

Yield

362.26%

 Dividend

$0.12

EX-DIVIDEND DATE

Nov 22, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.60M

  

VTRS Performance

1 Week
 
 4.21%
 
1 Month
 
 16.87%
 
3 Months
 
 13.69%
 
1 Year
 
 41.78%
 
5 Years
 
 N/A
 

VTRS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About viatris inc. - VTRS

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

VTRS At a Glance

Viatris, Inc.
Robert J. Coury Global Center
Canonsburg, Pennsylvania 15317
Phone 1-724-514-1800 Revenue 15.38B
Industry Pharmaceuticals: Major Net Income 54.70M
Sector Health Technology Employees 38,000
Fiscal Year-end 12 / 2024
View SEC Filings

VTRS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 239.073
Price to Sales Ratio 0.85
Price to Book Ratio 0.635
Price to Cash Flow Ratio 4.669
Enterprise Value to EBITDA 6.418
Enterprise Value to Sales 1.974
Total Debt to Enterprise Value 0.605

VTRS Efficiency

Revenue/Employee 404,778.947
Income Per Employee 1,439.474
Receivables Turnover 3.807
Total Asset Turnover 0.315

VTRS Liquidity

Current Ratio 1.572
Quick Ratio 1.126
Cash Ratio 0.139

VTRS Profitability

Gross Margin 42.699
Operating Margin 13.348
Pretax Margin 1.319
Net Margin 0.356
Return on Assets 0.112
Return on Equity 0.263
Return on Total Capital 0.141
Return on Invested Capital 0.144

VTRS Capital Structure

Total Debt to Total Equity 89.801
Total Debt to Total Capital 47.313
Total Debt to Total Assets 38.544
Long-Term Debt to Equity 79.90
Long-Term Debt to Total Capital 42.097
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Viatris Inc. - VTRS

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
11.94B 17.86B 16.17B 15.38B
Sales Growth
+3.83% +49.53% -9.42% -4.90%
Cost of Goods Sold (COGS) incl D&A
7.50B 11.66B 9.49B 8.81B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.22B 3.21B 2.85B 2.68B
Depreciation
527.90M 509.50M 349.50M 362.10M
Amortization of Intangibles
1.69B 2.70B 2.50B 2.32B
COGS Growth
+2.58% +55.39% -18.65% -7.08%
Gross Income
4.44B 6.20B 6.69B 6.57B
Gross Income Growth
+6.00% +39.62% +7.94% -1.80%
Gross Profit Margin
+37.16% +34.70% +41.35% +42.70%
2020 2021 2022 2023 5-year trend
SG&A Expense
3.06B 4.53B 4.18B 4.51B
Research & Development
507.50M 737.80M 660.80M 793.00M
Other SG&A
2.55B 3.79B 3.52B 3.72B
SGA Growth
-4.42% +47.90% -7.72% +8.03%
Other Operating Expense
- - - 16.90M
-
Unusual Expense
1.56B 1.69B 1.07B 1.28B
EBIT after Unusual Expense
(201.80M) (25.60M) 1.44B 777.20M
Non Operating Income/Expense
(26.10M) (6.90M) 1.96B 600.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - (48.40M) (61.90M)
-
Interest Expense
493.30M 631.90M 587.90M 574.90M
Interest Expense Growth
-3.31% +28.10% -6.96% -2.21%
Gross Interest Expense
493.30M 631.90M 587.90M 574.90M
Interest Capitalized
- - - -
-
Pretax Income
(721.20M) (664.40M) 2.81B 202.90M
Pretax Income Growth
-567.10% +7.88% +523.42% -92.79%
Pretax Margin
-6.04% -3.72% +17.39% +1.32%
Income Tax
(51.30M) 604.70M 734.60M 148.20M
Income Tax - Current - Domestic
(6.50M) 20.30M 141.80M 4.50M
Income Tax - Current - Foreign
(269.30M) (91.30M) 618.70M 530.80M
Income Tax - Deferred - Domestic
168.70M (193.50M) 284.00M 296.00M
Income Tax - Deferred - Foreign
55.80M 869.20M (309.90M) (683.10M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - (48.40M) (61.90M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(669.90M) (1.27B) 2.08B 54.70M
Minority Interest Expense
- - - -
-
Net Income
(669.90M) (1.27B) 2.08B 54.70M
Net Income Growth
-4,087.50% -89.45% +263.79% -97.37%
Net Margin Growth
-5.61% -7.11% +12.85% +0.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(669.90M) (1.27B) 2.08B 54.70M
Preferred Dividends
- - - -
-
Net Income Available to Common
(669.90M) (1.27B) 2.08B 54.70M
EPS (Basic)
-1.1143 -1.0499 1.7149 0.0456
EPS (Basic) Growth
-3,518.10% +5.78% +263.34% -97.34%
Basic Shares Outstanding
601.20M 1.21B 1.21B 1.20B
EPS (Diluted)
-1.1143 -1.0499 1.7074 0.0453
EPS (Diluted) Growth
-3,528.62% +5.78% +262.63% -97.35%
Diluted Shares Outstanding
601.20M 1.21B 1.22B 1.21B
EBITDA
3.57B 4.88B 5.36B 4.73B
EBITDA Growth
+26.68% +36.48% +9.92% -11.76%
EBITDA Margin
+29.94% +27.33% +33.16% +30.77%

Snapshot

Average Recommendation HOLD Average Target Price 12.833
Number of Ratings 10 Current Quarters Estimate 0.587
FY Report Date 12 / 2024 Current Year's Estimate 2.68
Last Quarter’s Earnings 0.75 Median PE on CY Estimate N/A
Year Ago Earnings 2.936 Next Fiscal Year Estimate 2.658
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 3 7 7
Mean Estimate 0.59 0.62 2.68 2.66
High Estimates 0.65 0.63 2.72 2.77
Low Estimate 0.54 0.61 2.65 2.50
Coefficient of Variance 6.80 1.69 1.10 3.63

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 2 2
OVERWEIGHT 0 0 1
HOLD 7 7 6
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Viatris Inc. - VTRS

Date Name Shares Transaction Value
Jun 18, 2024 Rajiv Malik Director 909,819 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.52 per share 9,571,295.88
Jun 18, 2024 Rajiv Malik Director 645,519 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.18 per share 6,571,383.42
Jun 5, 2024 Rogério Vivaldi Coelho Director 21,267 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Brian S. Roman Chief Legal Officer 67,723 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.38 per share 702,964.74
Mar 18, 2024 Anthony Mauro See Remarks 243,044 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.09 per share 2,938,401.96
Mar 6, 2024 Harry A. Korman Director 88,921 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Wyllie Don Cornwell Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Wyllie Don Cornwell Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Wyllie Don Cornwell Director 60,480 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Harry A. Korman Director 18,204 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Harry A. Korman Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Harry A. Korman Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Harry A. Korman Director 89,806 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Mark W. Parrish Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Mark W. Parrish Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Theodora Mistras Chief Financial Officer 93,447 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Mark W. Parrish Director 120,533 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Melina E. Higgins Director 18,204 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Melina E. Higgins Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Melina E. Higgins Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Viatris Inc. in the News